|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CDT1 |
Gene summary for CDT1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CDT1 | Gene ID | 81620 |
| Gene name | chromatin licensing and DNA replication factor 1 | |
| Gene Alias | DUP | |
| Cytomap | 16q24.3 | |
| Gene Type | protein-coding | GO ID | GO:0000070 | UniProtAcc | Q9H211 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 81620 | CDT1 | P38T-E | Human | Esophagus | ESCC | 4.51e-05 | 1.98e-01 | 0.127 |
| 81620 | CDT1 | P39T-E | Human | Esophagus | ESCC | 6.96e-03 | 2.38e-01 | 0.0894 |
| 81620 | CDT1 | P40T-E | Human | Esophagus | ESCC | 2.81e-03 | 2.96e-01 | 0.109 |
| 81620 | CDT1 | P42T-E | Human | Esophagus | ESCC | 6.52e-05 | 2.52e-01 | 0.1175 |
| 81620 | CDT1 | P47T-E | Human | Esophagus | ESCC | 4.85e-02 | 1.33e-01 | 0.1067 |
| 81620 | CDT1 | P48T-E | Human | Esophagus | ESCC | 2.95e-08 | 2.86e-01 | 0.0959 |
| 81620 | CDT1 | P52T-E | Human | Esophagus | ESCC | 2.25e-31 | 7.97e-01 | 0.1555 |
| 81620 | CDT1 | P54T-E | Human | Esophagus | ESCC | 2.34e-02 | 1.22e-01 | 0.0975 |
| 81620 | CDT1 | P61T-E | Human | Esophagus | ESCC | 5.23e-03 | 2.01e-01 | 0.099 |
| 81620 | CDT1 | P62T-E | Human | Esophagus | ESCC | 4.71e-11 | 6.31e-01 | 0.1302 |
| 81620 | CDT1 | P65T-E | Human | Esophagus | ESCC | 1.26e-04 | 2.01e-01 | 0.0978 |
| 81620 | CDT1 | P74T-E | Human | Esophagus | ESCC | 3.10e-04 | 2.45e-01 | 0.1479 |
| 81620 | CDT1 | P75T-E | Human | Esophagus | ESCC | 1.09e-07 | 2.74e-01 | 0.1125 |
| 81620 | CDT1 | P76T-E | Human | Esophagus | ESCC | 2.29e-11 | 2.88e-01 | 0.1207 |
| 81620 | CDT1 | P79T-E | Human | Esophagus | ESCC | 2.08e-07 | 2.52e-01 | 0.1154 |
| 81620 | CDT1 | P83T-E | Human | Esophagus | ESCC | 9.70e-15 | 6.52e-01 | 0.1738 |
| 81620 | CDT1 | P89T-E | Human | Esophagus | ESCC | 2.07e-03 | 3.93e-01 | 0.1752 |
| 81620 | CDT1 | P91T-E | Human | Esophagus | ESCC | 9.55e-07 | 8.99e-01 | 0.1828 |
| 81620 | CDT1 | P107T-E | Human | Esophagus | ESCC | 1.00e-21 | 6.62e-01 | 0.171 |
| 81620 | CDT1 | P128T-E | Human | Esophagus | ESCC | 1.63e-02 | 2.26e-01 | 0.1241 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:014001414 | Esophagus | ESCC | mitotic nuclear division | 218/8552 | 287/18723 | 6.17e-26 | 1.78e-23 | 218 |
| GO:005165617 | Esophagus | ESCC | establishment of organelle localization | 273/8552 | 390/18723 | 9.13e-23 | 1.81e-20 | 273 |
| GO:000007011 | Esophagus | ESCC | mitotic sister chromatid segregation | 138/8552 | 168/18723 | 1.37e-22 | 2.63e-20 | 138 |
| GO:00008194 | Esophagus | ESCC | sister chromatid segregation | 157/8552 | 202/18723 | 8.41e-21 | 1.33e-18 | 157 |
| GO:0051098111 | Esophagus | ESCC | regulation of binding | 251/8552 | 363/18723 | 6.73e-20 | 8.46e-18 | 251 |
| GO:1903829111 | Esophagus | ESCC | positive regulation of cellular protein localization | 199/8552 | 276/18723 | 2.99e-19 | 3.45e-17 | 199 |
| GO:003304416 | Esophagus | ESCC | regulation of chromosome organization | 145/8552 | 187/18723 | 3.80e-19 | 4.31e-17 | 145 |
| GO:000705911 | Esophagus | ESCC | chromosome segregation | 238/8552 | 346/18723 | 1.72e-18 | 1.82e-16 | 238 |
| GO:004477216 | Esophagus | ESCC | mitotic cell cycle phase transition | 281/8552 | 424/18723 | 4.63e-18 | 4.45e-16 | 281 |
| GO:0043254111 | Esophagus | ESCC | regulation of protein-containing complex assembly | 278/8552 | 428/18723 | 3.81e-16 | 2.77e-14 | 278 |
| GO:000734615 | Esophagus | ESCC | regulation of mitotic cell cycle | 293/8552 | 457/18723 | 8.00e-16 | 5.64e-14 | 293 |
| GO:00062604 | Esophagus | ESCC | DNA replication | 181/8552 | 260/18723 | 3.55e-15 | 2.05e-13 | 181 |
| GO:0031334111 | Esophagus | ESCC | positive regulation of protein-containing complex assembly | 166/8552 | 237/18723 | 2.06e-14 | 1.07e-12 | 166 |
| GO:005131011 | Esophagus | ESCC | metaphase plate congression | 58/8552 | 65/18723 | 1.81e-13 | 8.63e-12 | 58 |
| GO:005105215 | Esophagus | ESCC | regulation of DNA metabolic process | 232/8552 | 359/18723 | 2.40e-13 | 1.13e-11 | 232 |
| GO:000708011 | Esophagus | ESCC | mitotic metaphase plate congression | 47/8552 | 50/18723 | 3.15e-13 | 1.47e-11 | 47 |
| GO:00482853 | Esophagus | ESCC | organelle fission | 301/8552 | 488/18723 | 4.64e-13 | 2.12e-11 | 301 |
| GO:00988133 | Esophagus | ESCC | nuclear chromosome segregation | 187/8552 | 281/18723 | 1.00e-12 | 4.36e-11 | 187 |
| GO:005130311 | Esophagus | ESCC | establishment of chromosome localization | 67/8552 | 80/18723 | 1.92e-12 | 8.09e-11 | 67 |
| GO:005000011 | Esophagus | ESCC | chromosome localization | 68/8552 | 82/18723 | 3.37e-12 | 1.32e-10 | 68 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0411023 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
| hsa0411033 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
| hsa041102 | Liver | HCC | Cell cycle | 106/4020 | 157/8465 | 2.54e-07 | 3.04e-06 | 1.69e-06 | 106 |
| hsa041103 | Liver | HCC | Cell cycle | 106/4020 | 157/8465 | 2.54e-07 | 3.04e-06 | 1.69e-06 | 106 |
| hsa041108 | Oral cavity | OSCC | Cell cycle | 118/3704 | 157/8465 | 7.15e-16 | 2.66e-14 | 1.35e-14 | 118 |
| hsa0411015 | Oral cavity | OSCC | Cell cycle | 118/3704 | 157/8465 | 7.15e-16 | 2.66e-14 | 1.35e-14 | 118 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CDT1 | SNV | Missense_Mutation | c.545C>A | p.Pro182Gln | p.P182Q | Q9H211 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CDT1 | SNV | Missense_Mutation | novel | c.1018G>T | p.Val340Leu | p.V340L | Q9H211 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-E2-A574-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| CDT1 | SNV | Missense_Mutation | novel | c.468G>T | p.Glu156Asp | p.E156D | Q9H211 | protein_coding | tolerated(0.13) | benign(0.007) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CDT1 | SNV | Missense_Mutation | novel | c.466N>A | p.Glu156Lys | p.E156K | Q9H211 | protein_coding | tolerated(0.35) | benign(0.007) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| CDT1 | SNV | Missense_Mutation | novel | c.466G>A | p.Glu156Lys | p.E156K | Q9H211 | protein_coding | tolerated(0.35) | benign(0.007) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CDT1 | SNV | Missense_Mutation | novel | c.641C>A | p.Pro214His | p.P214H | Q9H211 | protein_coding | deleterious(0) | possibly_damaging(0.882) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| CDT1 | SNV | Missense_Mutation | c.1621C>T | p.Arg541Cys | p.R541C | Q9H211 | protein_coding | deleterious(0.02) | possibly_damaging(0.676) | TCGA-AD-6895-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
| CDT1 | SNV | Missense_Mutation | novel | c.310N>A | p.Ala104Thr | p.A104T | Q9H211 | protein_coding | tolerated(0.32) | benign(0.039) | TCGA-AP-A0LS-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CDT1 | SNV | Missense_Mutation | novel | c.1118C>T | p.Pro373Leu | p.P373L | Q9H211 | protein_coding | deleterious(0) | probably_damaging(0.948) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CDT1 | SNV | Missense_Mutation | novel | c.1065G>T | p.Glu355Asp | p.E355D | Q9H211 | protein_coding | tolerated(0.47) | benign(0.07) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |